Microbial APIs (active pharmaceutical ingredients) are pharmaceutical compounds produced using microbial fermentation processes. It is produced by growing microorganisms such as bacteria, fungi, or yeast and extracting the desired compound.
Sizing and Forecast
The microbial API market size has grown strongly in recent years. It will grow from $58.19 billion in 2023 to $62.90 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased demand for drugs, an increase in the focus of government on healthcare and pharmaceuticals, an increased need to meet nutritional requirements, sustainability and cost-efficiency, and a rise in demand for biological drugs.
The microbial API market size is expected to see strong growth in the next few years. It will grow to $86.22 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing applications in the pharmaceutical industry, the rising prevalence of chronic conditions, increasing health care expenditure, increasing access to advanced medical infrastructure, increasing infections and antibiotic resistance. Major trends in the forecast period include advancements in fermentation and downstream processing technologies, innovations in microbial fermentation technologies, investments in bioprocessing, advancements in molecular biology and synthetic biology, and product innovation.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/microbial-api-global-market-report
Segmentation & Regional Insights
The microbial api market covered in this report is segmented –
1) By Type: Antibody, Peptide, Protein, Small Molecule, Vaccine
2) By Host: Mammalian, Bacterial, Fungal
3) By Site: In-House, Outsourced
4) By Molecule: Innovative, Generic
5) By End-Use: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Uses
Asia-Pacific was the largest region in the microbial API market in 2023. The regions covered in the microbial api market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15861&type=smp
Major Driver Impacting Market Growth
The rising prevalence of chronic conditions is expected to propel the growth of the microbial API market going forward. A chronic condition is a long-lasting health condition or disease that is persistent or otherwise long-lasting in its effects. Chronic conditions are rising due to a combination of factors, including aging populations, sedentary lifestyles, poor diets, environmental changes, and increased detection and diagnosis of diseases. Microbial APIs are increasingly employed in the management of chronic conditions, leveraging their therapeutic properties derived from microorganisms to develop effective treatments. For instance, in July 2021, according to the International Diabetes Federation (IDF), a Belgium-based diabetes organization, the global number of people with diabetes is predicted to reach 537 million in 2021, 643 million in 2030, and 783 million in 2045, with an anticipated 541 million people having impaired glucose tolerance by 2021. Additionally, nearly 6.7 million individuals aged 20 to 79 are expected to die from diabetes-related complications in 2021. Therefore, the rising prevalence of chronic conditions is driving the growth of the microbial API market.
Key Industry Players
Major companies operating in the microbial api market are BASF SE, Merck& Co Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca Plc, GlaxoSmithKline Plc, Eli Lilly And Company, Boehringer Ingelheim GmbH, Amgen Inc., Evonik Industries AG, TEVA Pharmaceutical industries Ltd., Lonza Group AG, Catalent Inc., CSPC Pharmaceutical Group Ltd., Patheon, Dr. Reddy’s Laboratories Ltd., Siegfried Ltd., Recipharm AB, Shandong Lukang Pharmaceutical Co. Ltd., Tianjin Tianyao Pharmaceuticals Co. Ltd., Xellia Pharmaceuticals, Kolon Life Science Inc., Royal DSM NV, Henan Topfond Pharmaceutical Co. Ltd.
The microbial api market report table of contents includes:
1. Executive Summary
- Microbial API Market Characteristics
- Microbial API Market Trends And Strategies
- Microbial API Market – Macro Economic Scenario
- Global Microbial API Market Size and Growth
.
32. Global Microbial API Market Competitive Benchmarking
- Global Microbial API Market Competitive Dashboard
- Key Mergers And Acquisitions In The Microbial API Market
- Microbial API Market Future Outlook and Potential Analysis
- Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
